SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Deep Origin, the computational drug discovery company replacing guesswork with prediction in small molecule drug development, today ...

According to The Rundown AI on X, Isomorphic Labs’ drug-design system more than doubled AlphaFold 3 performance on the hardest protein-ligand cases, signaling major gains in structure-based drug ...

In 2025, the UK led European tech investment by a wide margin, raising €21.5 billion across 830 deals and topping investment volumes in every quarter of the year. Funding was driven by a small number ...

LAS VEGAS (KTNV) — After we first told you about a raid at a home in east Las Vegas, conducted by local and federal authorities, questions have been swirling. Even as new details emerged regarding the ...

Welcome to the ABI Animus Lab Tutorials repository! This project is a comprehensive collection of tutorials and examples designed for bioengineering simulations, supporting Python, C++, VItA, VTK, ...

The healthcare funding landscape was not particularly kind to the U.K. in 2025. Following Merck pulling out of its $1 billion expansion plans in London, it was evident that life science investments in ...

Follow this physics lab tutorial to learn how to plot electric field and electric potential. Step-by-step instructions make it easy to understand the concepts, visualize results, and apply theory to ...

According to Isomorphic Labs (@IsomorphicLabs), the company has entered into a strategic partnership with Johnson & Johnson Innovation (@JNJInnovation) to leverage Isomorphic's AI drug design engine ...

Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.

Add Yahoo as a preferred source to see more of our stories on Google. Demis Hassabis speaks during the 56th annual World Economic Forum (WEF) meeting in Davos, Switzerland, January 20, 2026.